European Respiratory Society Monograph, Vol. 88. 2020
ISBN (electronic): 978-1-84984-119-1
DOI: 10.1183/2312508X.erm8820
This Monograph provides an update on cardiovascular disease complications and treatment implications for respiratory diseases, based on current scientific evidence and considered from an epidemiological, pathophysiological and clinical point of view. This book also discusses the future challenges when studying the complex relationship between these two groups of disorders.
Preface John R. Hurst Eur Respir Monogr 2020; 88: vii |  |
Guest Editors
Eur Respir Monogr 2020; 88: viii-x |  |
Introduction Miguel Ángel Martínez-García, Jean-Louis Pépin, Mario Cazzola Eur Respir Monogr 2020; 88: xi-xiii |   |
List of abbreviations
Eur Respir Monogr 2020; 88: xiv |  |
Epidemiological aspects of cardiovascular and respiratory diseases Joan B. Soriano, Roberto Elosua Eur Respir Monogr 2020; 88: 1-11 |   |
Common pathophysiological pathways of the autonomic nervous system Damien Viglino, Francois Maltais, Renaud Tamisier Eur Respir Monogr 2020; 88: 12-30 |   |
Murine models of cardiovascular damage in lung diseases Isaac Almendros, Isabel Blanco, Maribel Marquina, Victor Ivo Peinado, Silvia Barril, Ana Motos, Rosanel Amaro, Mireia Dalmases Eur Respir Monogr 2020; 88: 31-46 |   |
Cardiovascular disease in COPD Paola Rogliani, Luigino Calzetta Eur Respir Monogr 2020; 88: 47-65 |   |
Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Josuel Ora, Francesco Cavalli, Mario Cazzola Eur Respir Monogr 2020; 88: 66-81 |   |
Chronic asthma and the risk of cardiovascular disease Franklin A. Argueta, Carlos L. Alviar, Jay I. Peters, Diego J. Maselli Eur Respir Monogr 2020; 88: 82-95 |   |
Cardiovascular implications in bronchiectasis Wei-jie Guan, Yong-hua Gao, David de la Rosa-Carrillo, Miguel Ángel Martínez-García Eur Respir Monogr 2020; 88: 96-107 |   |
Cardiovascular complications of cystic fibrosis Damian G. Downey, J. Stuart Elborn Eur Respir Monogr 2020; 88: 108-117 |   |
Cardiovascular consequences of sleep disordered breathing: the role of CPAP treatment Maria R. Bonsignore, Salvatore Gallina, Luciano F. Drager Eur Respir Monogr 2020; 88: 118-142 |   |
The heart in obesity hypoventilation syndrome Victor R. Ramírez Molina, Juan Fernando Masa, Francisco J. Gómez de Terreros Caro, Jaime Corral Peñafiel, Babak Mokhlesi Eur Respir Monogr 2020; 88: 143-153 |   |
Cardiovascular effects of innovative therapies in lung cancer Anne-Claire Toffart, Hélène Pluchart, Nicolas Girard Eur Respir Monogr 2020; 88: 154-166 |   |
Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases Etienne-Marie Jutant, Maria-Rosa Ghigna, David Montani, Marc Humbert Eur Respir Monogr 2020; 88: 167-183 |   |
Cardiovascular mortality and morbidity in pulmonary embolism Behnood Bikdeli, Carmen Rodríguez, Alberto García-Ortega, David Jiménez Eur Respir Monogr 2020; 88: 184-197 |   |
The cardiovascular system in idiopathic pulmonary fibrosis Sy Giin Chong, Toyoshi Yanagihara, Martin R.J. Kolb Eur Respir Monogr 2020; 88: 198-211 |   |
Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections Raúl Méndez, Paula González-Jiménez, Laura Feced, Enrique Zaldívar, Rosario Menéndez Eur Respir Monogr 2020; 88: 212-228 |   |
ß2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities Maria Gabriella Matera, Reynold A. Panettieri Eur Respir Monogr 2020; 88: 229-237 |   |
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Daiana Stolz, Mario Cazzola Eur Respir Monogr 2020; 88: 238-250 |   |
Impact of inhaled corticosteroids in patients with cardiovascular disease Dharani Narendra, Nicola A. Hanania Eur Respir Monogr 2020; 88: 251-263 |   |
Cardiovascular side-effects of common antibiotics Francesco Amati, Marta Di Pasquale, Marcos I. Restrepo, Judith Marin-Corral, Stefano Aliberti, Francesco Blasi Eur Respir Monogr 2020; 88: 264-278 |   |
The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis Roberta Fusco, Rosanna Di Paola, Salvatore Cuzzocrea, Maria Gabriella Matera, Clive Page Eur Respir Monogr 2020; 88: 279-286 |   |
Future challenges Don D. Sin Eur Respir Monogr 2020; 88: 287-299 |   |
Case 1 Hirohito Sano, Taizou Hirano, Akira Koarai, Masakazu Ichinose Eur Respir Monogr 2020; 88: 300-304 |   |
Case 2 Bruno Revol, Ingrid Jullian-Desayes, Renaud Tamisier, Marie Joyeux-Faure Eur Respir Monogr 2020; 88: 305-313 |   |
Case 3 Samia Rached, Rodrigo Athanazio Eur Respir Monogr 2020; 88: 314-317 |   |